Ares Financial Consulting
DYN icon

Ares Financial Consulting’s Dyne Therapeutics DYN Stock Holding History

Ares Financial Consulting’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-84
Closed -$1.87K – 1091
2026
Q2 		$1.87K Buy
+84
New +$1.56K ﹤0.01% 901

Other funds holding DYN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Ares Financial Consulting's DYN Position: Q3 2026 in Review

Ares Financial Consulting sold out of Dyne Therapeutics (DYN) in Q3 2026, closing a stake of 84 shares — an estimated $1.87K sold.

Ares Financial Consulting first reported a position in DYN in Q2 2026 and held it in 1 quarter. The position peaked at $1.87K in Q2 2026. 179 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Ares Financial Consulting reported no remaining Dyne Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 84 Dyne Therapeutics shares in Q3 2026, an estimated $1.87K.
  • Ares Financial Consulting first reported a position in Dyne Therapeutics in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Dyne Therapeutics position peaked at $1.87K in Q2 2026.
  • 179 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.